|
Jul 15
|
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
|
|
Jun 27
|
India's Biocon drops plan to launch weight-loss drugs in China, executive says
|
|
Jun 27
|
Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
|